Cargando…
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
The remarkable progress in engineering and clinical development of therapeutic antibodies in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by the United States Food and Drug Administration (FDA) of 21 antibodies for cancer immunotherapy. We review here the...
Autores principales: | Almagro, Juan C., Daniels-Wells, Tracy R., Perez-Tapia, Sonia Mayra, Penichet, Manuel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770808/ https://www.ncbi.nlm.nih.gov/pubmed/29379493 http://dx.doi.org/10.3389/fimmu.2017.01751 |
Ejemplares similares
-
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
por: Candelaria, Pierre V., et al.
Publicado: (2021) -
Phage Display Libraries for Antibody Therapeutic Discovery and Development
por: Almagro, Juan C., et al.
Publicado: (2019) -
Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma
por: Daniels-Wells, Tracy R., et al.
Publicado: (2023) -
Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells
por: Plotkin, Jesse D., et al.
Publicado: (2019) -
A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma
por: Candelaria, Pierre V., et al.
Publicado: (2023)